Why It Matters
IQVIA faces a critical regulatory inflection point as Congress advances comprehensive health data privacy legislation that would fundamentally restrict how the company aggregates and monetizes health information. The Health Information Privacy Reform Act (S.3097) would extend HIPAA-like protections to non-covered entities like IQVIA, imposing new authorization requirements for accessing sensitive data.
Simultaneously, the FDA is modernizing data standards for clinical submissions and expanding acceptance of real-world evidence, creating new market opportunities. IQVIA’s $60,000 quarterly engagement with Republic Consulting LLC reflects strategic necessity to monitor privacy frameworks while positioning for FDA’s growing appetite for real-world data.
By the Numbers
IQVIA Inc. paid Republic Consulting LLC $60,000 for Q4 2025 lobbying work, continuing their longstanding relationship.
IQVIA has accumulated $2.66 million in lobbying spending across 62 filings since 2019, employing a diversified three-firm strategy. Republic Consulting remains IQVIA’s primary partner with 29 filings totaling $1.68 million. Atlas Crossing LLC joined in 2022 with 17 filings for $820,000 on drug pricing and cybersecurity. Horizon Government Affairs handles clinical trial policy with 16 filings worth $160,000.
Lobbyist Jody Hoffman continues representing IQVIA and previously handled predecessor IMS Health Inc. from 2003-2019, bringing two decades of health policy expertise.
The Agenda
IQVIA Inc. is lobbying broadly on federal health data policy, monitoring Congress on health issues, medical research, and pharmacy matters without targeting specific legislation this quarter.
The legislative landscape includes The Health Information Privacy Reform Act (S.3097) expanding privacy protections to health data brokers, the Right Drug Dose Now Act (H.R.2471) promoting pharmacogenomic data integration, and the BRAIN Act (S.1330) mandating clinical trial transparency.
IQVIA’s broad monitoring approach suggests positioning for multiple policy outcomes rather than backing specific bills, reflecting both opportunities from FDA modernization efforts and constraints from growing congressional scrutiny of health data privacy.
Broader Context
Congress is undertaking the most significant expansion of federal health data privacy authority since HIPAA. The Health Information Privacy Reform Act would impose new restrictions on data access requiring written authorization before IQVIA can receive patient information.
Simultaneously, regulatory shifts create opportunities. The FDA has removed key limitations on real-world evidence in medical device reviews, expanding demand for IQVIA’s analytics services. The bipartisan Right Drug Dose Now Act would boost pharmacogenomics integration, generating new datasets for analysis.
Healthcare data security has become politically volatile after more than 35 million individuals were affected by breaches in 2025, creating acute scrutiny of organizations handling health information at scale.
The Bottom Line
IQVIA Inc. continues investing in federal health data policy advocacy, retaining Republic Consulting LLC for $60,000 in fourth quarter 2025 as part of a multi-firm strategy totaling $2.66 million since 2019.
The engagement reflects IQVIA’s need to navigate a complex environment where lawmakers debate privacy restrictions and patient data protections while the FDA modernizes standards and expands real-world evidence acceptance. With longtime lobbyist Jody Hoffman representing the company, IQVIA maintains broad monitoring across health data policy, clinical trials, and pharmaceutical issues—managing both regulatory constraints and emerging opportunities for a business built on data aggregation.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article